Lupin’s arm receives USFDA approval for generic Zithromax Oral Suspension

01 Sep 2016 Evaluate

Gavis Pharmaceuticals LLC., USA, wholly owned subsidiary of Lupin, has received  tentative approval from the United States Food and Drug Administration (USFDA) for its Azithromycin for oral suspension USP, 300 mg (100 mg/5 mL) and 1200 mg (200 mg/5 mL) to market a generic version of Pfizer Inc.'s Zithromax for oral suspension, 100 mg/5ml and 200 mg/5ml. Lupin had earlier received final approval for its Azithromycin Tablets, 250 mg, 500 mg, 600 mg and Azithromycin for Oral Suspension USP, 100 mg/5 mL and 200 mg/5 mL from the USFDA which was filed from its Goa plant. Zithromax Oral Suspension had US sales of $110.6 million as per IMS MAT June 2016.

Lupin is a pharmaceutical company and is engaged in formulation of drugs and active pharmaceutical ingredients (APIs), generics, biotechnology, novel drug discovery and development, drug delivery systems and specialty pharmaceuticals. The firm offers products in various therapeutic areas such as anti-tuberculosis, cephalosporins, cardiovascular, anti-asthma, anti-infectives, pain reliever, diabetes, pediatrics, gynecology and non-steroidal anti-inflammatory drugs as well as ace inhibitors, statins and prils.

Lupin Share Price

2125.70 7.45 (0.35%)
19-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1745.10
Dr. Reddys Lab 1278.90
Cipla 1517.00
Zydus Lifesciences 919.85
Lupin 2125.70
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×